Alex Goldberg

NASDAQ Gainers Watch List: American Airlines Group Inc. (NASDAQ:AAL) and Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Added to Equity Profile Report's NASDAQ Gainers Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/03/2014 -- Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding American Airlines Group Inc. (NASDAQ:AAL) and Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).

American Airlines Group Inc. (NASDAQ:AAL) a company that through its subsidiaries, operates in the airline industry is currently up (+0.48%) on 5,463,483 shares traded. American Airlines Group Inc. (NASDAQ:AAL) is currently up (+171.5%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about American Airlines Group Inc. (NASDAQ:AAL)

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) a company that engages in the research and development of biotechnology product candidates in the areas of oncology and therapeutics worldwide is currently up (+3.35%) on 678,738 shares traded after Progenics Pharm has been upgraded by Needham. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is currently up (+104.74%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com